# Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Study · id `cardio:ct-nct02130453` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02130453](<https://clinicaltrials.gov/study/NCT02130453>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02130453

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

## Technical summary

Registry record NCT02130453. Non-randomized; single masking; primary purpose diagnostic. Start 2014-09-30 (actual); primary completion 2024-06-28 (actual). Results posted on 2024-10-02.

## Key facts

- Design: Interventional study; non-randomized; single masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 161 participants (enrolled count; ClinicalTrials.gov record NCT02130453, source copy `cardio:ctgov-nct02130453-2024-10-02`, retrieved 2026-10-26)
- Started: 2014-09-30 (actual) (ClinicalTrials.gov record NCT02130453, source copy `cardio:ctgov-nct02130453-2024-10-02`, retrieved 2026-10-26)
- Primary completion: 2024-06-28 (actual) (ClinicalTrials.gov record NCT02130453, source copy `cardio:ctgov-nct02130453-2024-10-02`, retrieved 2026-10-26)
- Completion: 2024-06-28 (actual) (ClinicalTrials.gov record NCT02130453, source copy `cardio:ctgov-nct02130453-2024-10-02`, retrieved 2026-10-26)
- Results first posted: 2024-10-02 (ClinicalTrials.gov record NCT02130453, source copy `cardio:ctgov-nct02130453-2024-10-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02130453, source copy `cardio:ctgov-nct02130453-2024-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02130453-2024-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
- Condition: Ischemia
- Intervention (Drug): Regadenoson
- Lead sponsor: M.D. Anderson Cancer Center
- Lead sponsor class: OTHER
- Collaborator: Astellas Scientific & Medical Affairs, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 26bd3eff465d4cd858748f7a80f1206eca3fe368cc91d280809764b7a49641ff
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
